← Back to the library
Published

Melanotan II

MT-II

A synthetic melanocortin-receptor agonist marketed for tanning, with no approval anywhere and a notable record of serious adverse events — safety is the dominant fact.

3
Primary sources
Preclinical
Evidence stage
Jul 2026
Last reviewed

This page describes where Melanotan II has been studied, not what it will do for you. Findings here come largely from animal and cell models and do not establish safety or benefit in humans. Nothing here is medical advice, and Proven Panel sells nothing.

What it is

Melanotan II (MT-II) is a synthetic non-selective melanocortin-receptor agonist, marketed for skin tanning.S1

Marketed as

Melanotan II is marketed as a "tanning" peptide (the "Barbie drug") for a sunless tan, and sometimes falsely as sun or skin-cancer protection. These are marketing claims for an unapproved, illegally sold product — and the safety record below is the dominant fact.S2

Regulatory status (US)

MT-II is not FDA-approved and has not received regulatory approval in any jurisdiction.S1S2 On FDA's compounding framework, Melanotan II appears in the "nominated but withdrawn" portion of Category 2.S1 FDA has issued consumer warnings about unapproved tanning products of this type.S2

⚑ Provisional

Trade / association reporting places Melanotan II in a reported ~February 2027 PCAC batch. Treat that date as provisional until an FDA / Federal Register notice confirms it. S2

Around the world

Melanotan II is unapproved essentially everywhere. The UK banned its sale and supply, and health authorities warn against it.S3 Australia's TGA and EU regulators likewise treat it as an unapproved product rather than a licensed medicine.S1S2 It's the same illegal gray-market product across borders.

Safety

Safety is the dominant fact about MT-II. Published case reports associate its use with melanoma / accelerated atypical nevus change, ischemic priapism, rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome (PRES), along with cardiovascular effects (hypertension, tachycardia) and severe nausea/vomiting.S2

Evidence

There are no completed Phase 3 trials establishing a safe, effective dose range in humans; the therapeutic evidence base is essentially absent.S2

Anti-doping

MT-II is a melanocortin agonist, not a peptide hormone or growth factor; its WADA status is not clearly that of a named prohibited substance. This should be confirmed directly before it is stated without qualification.

What's changing

The reported PCAC review is the near-term regulatory item, but the safety record above is the through-line regardless of compounding status.S2

Sources

Every reference below is a primary source cited in this entry, drawn from the approved corpus.

  1. 01
  2. 02
  3. 03
    Cancer Research UK — Tanning, fake tan and Melanotan
    cancerresearchuk.org · Cancer charity health information

Follow this compound

Get an email when FDA / WADA / ClinicalTrials moves on Melanotan II.

Follow this

The Panel Brief

What moved in supplement & peptide regulation this week. Free, cited, unsubscribe anytime.

You must be 18 or older to create an account.